in pictures and a few words
What it is and why it matters
The kidneys clean the blood through a filter made of three layers. The first layer is the vessel wall, coated with a thin protective gel: it keeps protein in the blood from passing into urine.
- In diabetes the gel wears away first — years before protein shows up in urine
- Routine kidney tests notice only a late stage
- If the damage is caught early, it can be stopped
What wears the protective layer away
Each of these causes speeds up the damage on its own. Together they act more strongly.
- High blood sugar, even in prediabetes, and high blood pressure
- “Bad” cholesterol and belly fat: a waist over 94 cm in men, 80 cm in women
- Smoking and a lack of vitamin D
Which tests to take
If you have had diabetes for more than 5 years, start with simple tests. The doctor picks the full set at a consultation.
- Protein and creatinine in a morning urine sample — not in 24-hour urine
- Cystatin C in the blood: in thin and older people it reveals damage earlier than creatinine
- Average blood sugar over three months, cholesterol and vitamin D
Sugar and blood pressure targets
In diabetes, keeping blood sugar, blood pressure and cholesterol on target is an essential part of protecting the kidneys.
- Blood pressure below 130/80, and if there is protein in urine — below 120/80
- Glycated hemoglobin below 7%, and below 6.5% if this is possible without sugar drops
- “Bad” cholesterol below 70 mg/dL (1.8 mmol/L), with protein in urine — below 55 mg/dL (1.4 mmol/L)
Medicines that protect the kidneys
Part of the protection is ordinary medicines. A doctor prescribes them, and there is no need to stop them out of fear for the kidneys.
- Empagliflozin or dapagliflozin — diabetes medicines that reduce protein in urine
- With protein in urine, the first treatment is blood pressure pills from two special groups
- A small rise in creatinine in the first weeks is usually normal; the doctor assesses it
Food and movement
A Mediterranean plate and daily movement help blood vessels, including those in the kidneys.
- Olive oil, fish, vegetables, nuts, legumes
- Fewer juices, syrups, agave and fast carbs: fruit sugar harms the gel
- Endurance exercise — from 30 minutes a day
Important. If kidney function is already reduced, decide with a doctor or nutritionist how much protein to eat: excess protein makes it worse.
Supplements — on a doctor’s plan
The article describes a set of remedies for the protective gel and blood vessels. It is tailored to the person, and with reduced kidney function the doses are adjusted with a doctor.
- For the protective gel — the medicine sulodexide, glucosamine and chondroitin
- Arginine and citrulline — raw material for a substance that keeps vessels from narrowing
- Fish oil, vitamins D, K2 and C, magnesium, pomegranate, cocoa and turmeric extracts
Important. If you take blood thinners, take sulodexide, fish oil and curcumin only after talking to a doctor.
What to avoid
Some everyday things harm the kidneys, especially with diabetes and high blood pressure.
- Long-term ibuprofen, diclofenac and similar drugs: they reduce blood flow to the kidneys
- For pain — paracetamol no more than 3 g a day, pain-relief gels or physiotherapy
- Vitamin D above 4000 IU (100 mcg) a day for a long time — only with test monitoring
Important. After a recent heart attack, arginine and citrulline are not prescribed.
Who should see a doctor first
Talk to a doctor about a kidney check if you have at least one of these.
- Diabetes or high blood pressure for more than 5 years, extra belly fat
- Prediabetes — glycated hemoglobin 5.7–6.4% — and kidney disease in relatives
- Protein in urine even once, acute kidney injury in the past, including with COVID
Important. Blood in urine, a fast drop in kidney function or a lot of protein — the cause may not be diabetes. Tests come first.
In one sentence
In diabetes, kidney damage starts with the protective gel of the vessels, long before protein appears in urine. Early tests, sugar and blood pressure targets and medicines from a doctor help preserve it.
Introduction: where CKD really begins
When people discuss chronic kidney disease in a person with diabetes, the image that often comes to mind is an injured podocyte — a cell with interlacing foot processes that maintains the filtration slit. This is true, but it is already a late stage. The real start of injury occurs one level upstream — in the glomerular endothelium (GEnC), the thin lining of the glomerular capillaries.
GEnC is not "ordinary blood vessels." It is a specialized vascular filter with two unique features: 70–100 nm fenestrations (open windows without diaphragms) and a 200–400 nm thick anionic glycocalyx — a gel-like layer of proteoglycans and sialoglycoproteins that maintains a negative charge and prevents albumin from entering the primary urine.
In other words: CKD in diabetes begins not in the podocyte, but in the endothelium. And it begins long before creatinine or the urine albumin/creatinine ratio moves outside the reference range. If it is detected at this stage, the cascade can be stopped.
🌀
GEnC architecture: a three-layer filter
The glomerular filtration barrier is a composite structure with three layers. Each has its own function, and each is necessary:
▸Glomerular endothelium (GEnC) with the glycocalyx — the first and earliest layer. The 70–100 nm fenestrations allow water and electrolytes to pass, while the glycocalyx blocks albumin and other anionic proteins through charge-selectivity. ▸Glomerular basement membrane (GBM) — the middle layer, approximately 300 nm thick, composed of type IV collagen, laminin, nidogen, and heparan sulfate proteoglycans. It provides an additional size and charge barrier. ▸Podocytes with slit diaphragms — the outer layer; nephrin and podocin form the molecular zipper of the approximately 40 nm filtration slit. This is the final line of defense.
All three layers work as a single system. But injury begins from the inside outward: first the endothelium and its glycocalyx, then the GBM, then the podocyte. Standard tests (creatinine, urine albumin) detect only the third stage — when the podocyte is already disrupted and protein begins to leak into the urine.
The total area of GEnC fenestrations is approximately 25% of the entire glomerular surface. This is a large active membrane that filters about 180 liters of plasma per day in an adult. Any disturbance of its function has immediate systemic consequences.
🌀
Mechanisms of GEnC injury
Glomerular endothelial dysfunction is not a single all-at-once failure, but a cascade with two key events: reduced NO bioavailability and glycocalyx shedding.
▸Reduction in eNOS-dependent NO. Under normal conditions, GEnC eNOS (endothelial NO synthase) maintains capillary tone, thromboresistance, and glycocalyx permeability. Hyperglycemia and oxidative stress uncouple eNOS: the enzyme stops producing NO and begins producing superoxide. NO falls, endothelin-1 rises, and vasoconstriction and fibrosis begin. ▸Glycocalyx shedding. Hyperglycemia glycates proteoglycans (syndecan-1, perlecan, versican) and activates heparanase-1 and hyaluronidase-1, which "shave off" the glycocalyx. The anionic charge disappears, and albumin begins to seep through. This is microalbuminuria — but by the time it appears, 30–60% of the glycocalyx has already been lost. ▸Oxidized LDL via the LOX-1 receptor. GEnC expresses LOX-1, which binds oxidized LDL and induces endothelial apoptosis. In a person with diabetes and dyslipidemia, this doubles the rate of injury. ▸Sepsis and SARS-CoV-2. Acute conditions trigger massive glycocalyx shedding through bacterial heparanase or direct viral cytopathic effects. This explains the frequent AKI seen in COVID-19 and sepsis among patients with already subclinical GEnC dysfunction. ▸Chronic inflammation. TNF-α and IL-6 from visceral fat keep the endothelium in an activated state: increased VCAM-1 and ICAM-1 expression, and NF-κB activation.
After 5–10 years, glycocalyx shedding reaches the threshold at which microalbuminuria appears (30–300 mg/g in a morning sample). After 10–15 years, macroalbuminuria and declining eGFR develop. Standard nephrology sees only these final stages. The early window remains invisible.
🌀
Drivers of GEnC injury
Seven factors independently accelerate glomerular endothelial injury. In combination, their effect is multiplicative.
•Hyperglycemia and AGE products. Glucose directly glycates glycocalyx proteoglycans and activates RAGE receptors. Even prediabetes with HbA1c 5.7–6.4% is accompanied by subclinical syndecan-1 shedding. •Arterial hypertension. Every 10 mm Hg of systolic pressure above 130 accelerates glycocalyx degradation and increases endothelin-1. Target in the md_pereligyn protocol: BP <130/80 for a person with diabetes, <120/80 for a patient with already detected microalbuminuria. •Dyslipidemia and oxidized LDL. sdLDL and oxLDL bind to LOX-1 on GEnC and induce apoptosis. Target LDL in a patient with diabetes: <70 mg/dL; with microalbuminuria present — <55 mg/dL. •ADMA — asymmetric dimethylarginine. An endogenous eNOS inhibitor; its concentration rises in CKD, diabetes, and hypertension. •Visceral fat and systemic inflammation. TNF-α, IL-6, and resistin keep GEnC in an activated state. Waist circumference >94 cm (men) / >80 cm (women) is a risk factor independent of BMI. •Smoking. Nicotine reduces eNOS, while carbon monoxide displaces NO from hemoglobin. In smokers with diabetes, the rate of nephropathy progression is 2.5 times higher. •Vitamin D deficiency (<30 ng/mL). Vitamin D regulates eNOS expression and inhibits RAAS activation in the kidney. Deficiency is associated with increased ADMA and faster progression of albuminuria.
🌀
Early biomarkers of GEnC dysfunction
The standard nephrology panel — creatinine, urea, CKD-EPI eGFR, urine albumin/creatinine ratio — detects the kidney at CKD stage 3 and later. Early GEnC injury requires different markers:
| Marker | Threshold |
|---|---|
| Syndecan-1 | < 50 ng/mL |
| ACR (microalbuminuria) | 30–300 mg/g |
| Brachial artery FMD | < 4% |
| Target LDL with microalbuminuria | < 55 mg/dL |
▸Serum syndecan-1 — a glycocalyx fragment and marker of active shedding. Normal <50 ng/mL; elevation indicates ongoing GEnC injury. Available in specialized laboratories (Germany, USA). ▸Serum ADMA and SDMA — direct markers of eNOS inhibition and systemic endothelial dysfunction. They rise 5–10 years before eGFR declines. ▸Soluble VCAM-1 (sVCAM-1) — an indicator of endothelial activation, elevated in subclinical vascular inflammation. ▸Cystatin C — a filtration marker independent of muscle mass. It rises earlier than creatinine in lean and elderly patients. ▸Microalbuminuria (ACR 30–300 mg/g) — already a late marker: by the time it appears, 30–60% of the GEnC glycocalyx has been lost. ▸Nailfold capillaroscopy — a surrogate visual marker of microvascular dysfunction associated with GEnC status. ▸Brachial artery FMD <4% — a marker of systemic endothelial dysfunction that also reflects the renal endothelium.
A detailed review of what the standard kidney panel really shows and where its blind spots are can be found in the article Creatinine lies: the limits of the standard kidney panel.
🌀
Holistic protocol for GEnC restoration
The principle of the md_pereligyn protocol: treatment is directed not at creatinine, but at the endothelium and the glycocalyx. Restoring the NO pool and restituting the glycocalyx stops the nephropathy cascade years before dialysis or transplantation becomes necessary.
1. NO precursors
▸L-arginine 3–6 g/day — an eNOS substrate; divide into 2–3 doses on an empty stomach. ▸L-citrulline 3 g/day — bypasses first-pass hepatic arginase, more reliably increases plasma arginine and renal NO. ▸Betaine (trimethylglycine) 1500 mg — lowers homocysteine (an independent factor in GEnC injury), a remethylation cofactor.
2. Glycocalyx stabilizers
▸Sulodexide 250 LSU twice daily — a heparinoid; small studies showed partial glycocalyx restoration (PMID 20865240) and dose-dependent albuminuria reduction (Di.N.A.S., PMID 12039991); the large Sun-MICRO trial showed no effect (PMID 21872376) — the evidence is mixed. ▸Glucosamine sulfate 1500 mg — a substrate for synthesis of glycocalyx heparan sulfates. ▸Chondroitin sulfate 1200 mg — support for the proteoglycan component.
3. Antioxidant protection
▸Vitamin C 500–1000 mg — regenerates tetrahydrobiopterin (BH4), an eNOS cofactor, and prevents eNOS uncoupling in GEnC. ▸N-acetylcysteine (NAC) 600–1200 mg — a glutathione precursor, shown to reduce oxidative stress in the kidney. ▸Alpha-lipoic acid 600 mg — a dual-soluble antioxidant that regenerates glutathione and vitamin C.
4. Polyphenols — BH4 regeneration and endothelial protection
▸Pomegranate (extract) 250–500 mg — punicalagin, with demonstrated effects on FMD and systemic endothelial function. ▸Cocoa (flavanols) 500 mg — epicatechin, increases NO bioavailability. ▸Curcumin (liposomal) 500 mg — reduces TNF-α and NF-κB, protecting GEnC from inflammatory injury. ▸Quercetin 500 mg — antioxidant, lowers BP.
5. Omega-3
▸EPA+DHA 2–3 g/day — reduces TNF-α, IL-6, and systemic inflammation. ▸Check the omega-3 index every 4–6 months; target >8%. ▸Quality is critical: fish oil must be tested for oxidation (TOTOX <26).
6. Vitamin D and magnesium
▸Vitamin D3 — dose guided by 25(OH)D, usually up to 4,000 IU (100 mcg)/day, to at least 30 ng/mL (75 nmol/L); higher doses only short-term to correct deficiency, with 25(OH)D, calcium and PTH monitoring. Regulates RAAS and eNOS expression in the kidney. ▸Magnesium (glycinate / taurate) 400 mg — an eNOS cofactor, lowers BP, and directly relaxes blood vessels. ▸Vitamin K2 (MK-7) 100–200 mcg — directs calcium into bone and protects against renal artery calcification.
7. Glycemic and BP control
▸HbA1c <7% — a mandatory target, ideally <6.5% without hypoglycemia when possible. ▸BP <130/80 for a person with diabetes without albuminuria, <120/80 when microalbuminuria is present. ▸SGLT2 inhibitors (empagliflozin, dapagliflozin) — demonstrated nephroprotective effect (DAPA-CKD, Heerspink HJL, NEJM 2020, PMID 32970396). Reduce albuminuria and slow eGFR decline. ▸ACE inhibitors or ARBs for microalbuminuria — standard first-line therapy.
8. Nutrition and movement
▸Mediterranean / DASH pattern — olive oil, fish, vegetables, nuts, legumes. Low in AGE products. ▸Protein restriction to 0.8 g/kg/day when eGFR <60, and to 0.6 g/kg/day when eGFR <30 (under dietitian supervision). ▸Restriction of fructose and fast carbohydrates — fructose directly injures the glycocalyx. ▸Aerobic activity 30+ minutes/day — laminar shear stress activates eNOS in the systemic endothelium, including GEnC.
🌀
What does NOT work (and why)
▸Isolated creatinine monitoring without assessing the glycocalyx and microalbuminuria — misses the early window. Creatinine remains normal until approximately ~50% of filtration is lost. ▸Long-term NSAIDs (ibuprofen, diclofenac) — reduce renal blood flow and accelerate GEnC injury. In patients with diabetes and hypertension, they increase AKI risk by 40–60%. ▸High-protein diets (>1.5 g/kg/day) with reduced eGFR — increase hyperfiltration and accelerate glomerulosclerosis. ▸Excess fructose (juices, agave, syrups) — directly injures the glycocalyx and causes hyperuricemia. ▸Vitamin D above 4,000 IU (100 mcg)/day long-term without 25(OH)D and calcium monitoring — risk of hypercalcemia. ▸Avoiding ACE inhibitors/ARBs out of fear that "they harm the kidneys" — in fact, they provide proven nephroprotection in microalbuminuria. A transient creatinine rise of 20–30% is expected and is not a reason to stop therapy.
🌀
When to seek care
▸Type 1 or type 2 diabetes for more than 5 years ▸Prediabetes with HbA1c 5.7–6.4% and a family history of CKD ▸Arterial hypertension for more than 5 years ▸Microalbuminuria in a single test (requires confirmation and expanded diagnostics) ▸Metabolic syndrome, visceral obesity ▸Family history of CKD, dialysis, kidney transplantation ▸A previous episode of AKI (including COVID-19, sepsis, contrast-induced nephropathy)
I perform full screening for early diabetic nephropathy (syndecan-1, ADMA, cystatin C, ACR, eGFR-CKD-EPI 2021, expanded lipid panel) and prepare a personalized protocol for GEnC restoration and glycocalyx stabilization.
🌀
Conclusion
Chronic kidney disease in a person with diabetes begins not in the podocyte, but in the glomerular endothelium. Glycocalyx shedding and reduction of the NO pool precede microalbuminuria by 5–10 years, and structural podocyte injury by 8–12 years. This is the earliest intervention window in which reversibility has been demonstrated.
The holistic protocol — NO precursors, glycocalyx stabilizers (sulodexide, glucosamine), antioxidants, polyphenols, omega-3, vitamin D + K2, glycemic and BP control, SGLT2 inhibitors — restores GEnC and stops the nephropathy cascade years before creatinine or urine albumin leaves the normal range.
Treatment should target the endothelium, not its complications.
🌀
Sources
▸Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med 2020;383:1436–1446. PMID 32970396
Related articles: Endothelium: the foundation of vascular health, Cholesterol without statins.
🌀
FAQ
Can the glomerular endothelial glycocalyx be restored? Partly, in studies. Sulodexide 200 mg/day for 2 months partly restored glycocalyx thickness (n=10); in Di.N.A.S. it cut albuminuria by 30–74% depending on dose over 4 months; the large Sun-MICRO trial showed no effect. The foundation is glucose and BP control, ACEi/ARB and SGLT2 inhibitors.
Which tests should be done first if diabetes has been present for 5+ years? Minimum: ACR (albumin/creatinine ratio in a morning sample, not 24-hour urine!), cystatin C, CKD-EPI 2021 eGFR (creatinine + cystatin), HbA1c, expanded lipid panel with sdLDL and Lp(a), 25(OH)D. If possible — syndecan-1, ADMA, homocysteine. The full panel is determined during consultation.
Is it safe to take SGLT2 inhibitors with reduced eGFR? Yes, down to eGFR 20 mL/min/1.73 m² according to the latest KDIGO 2024 recommendations. The key is to monitor dehydration, genital infection risk, and ketoacidosis. A transient creatinine rise of 10–20% during the first 4 weeks is expected and reflects a hemodynamic reduction in hyperfiltration.
How soon should albuminuria decrease after starting the protocol? With the combination of ACE inhibitor/ARB + SGLT2 + BP control, ACR usually decreases, but the size and timing of the decrease vary between patients; the contribution of sulodexide was not confirmed in a large trial (Sun-MICRO, PMID 21872376). Monitor every 3 months. If there is no effect after 6 months, the protocol should be reassessed, adherence checked, and secondary causes excluded (non-diabetic nephropathy).
Can L-arginine be taken in CKD? Yes, when eGFR >45 mL/min/1.73 m² it is safe at 3–6 g/day under monitoring. With eGFR 30–45, reduce to 2–3 g/day. With eGFR <30, only under individualized nephrologist supervision, because amino acid load increases urea.
This article is for informational purposes only and is not a substitute for professional medical advice. Discuss any nutraceutical, medication adjustment, or diagnostic procedure with your treating physician before starting.
Key facts
- The glomerular endothelium has 70–100 nm fenestrations and a 200–400 nm anionic glycocalyx.
- GEnC dysfunction precedes microalbuminuria by 5–10 years and podocyte injury by 8–12 years.
- Glomerular injury proceeds from the inside outward: endothelium and glycocalyx, then GBM, then podocyte.
- GEnC fenestrations cover ~25% of the glomerular surface and filter ~180 L of plasma per day.
- By the time microalbuminuria appears, 30–60% of the GEnC glycocalyx is already lost.




